Literature DB >> 7731544

Apolipoprotein E polymorphism and Alzheimer's disease in eastern Finland.

M Lehtovirta1, S Helisalmi, A Mannermaa, H Soininen, K Koivisto, M Ryynänen, P Riekkinen.   

Abstract

Apolipoprotein E is a polymorphic protein defined by three alleles, epsilon 2, epsilon 3 and epsilon 4. An increased frequency of the epsilon 4 allele is associated with late-onset familial and sporadic Alzheimer's disease (AD). We studied 202 Finnish AD patients and 55 age- and sex-matched controls. AD patients were divided into four subgroups; sporadic early-onset, sporadic late-onset, familial early-onset and familial late-onset disease. We found no significant differences in the epsilon 4 allele frequency between the subgroups. However, all the subgroups differed in the frequency of epsilon 4 allele detection from the controls (P < 0.0001). In the late-onset patients, the age at onset decreased from 76 to 69 as the number of epsilon 4 alleles increased from 0 to 2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731544     DOI: 10.1016/0304-3940(94)11213-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

Review 1.  Limitations and risks of meta-analyses of longevity studies.

Authors:  Paola Sebastiani; Harold Bae; Anastasia Gurinovich; Mette Soerensen; Annibale Puca; Thomas T Perls
Journal:  Mech Ageing Dev       Date:  2017-01-28       Impact factor: 5.432

2.  Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.

Authors:  H Bickeböller; D Campion; A Brice; P Amouyel; D Hannequin; O Didierjean; C Penet; C Martin; J Pérez-Tur; A Michon; B Dubois; F Ledoze; C Thomas-Anterion; F Pasquier; M Puel; J F Demonet; O Moreaud; M C Babron; D Meulien; D Guez; M C Chartier-Harlin; T Frebourg; Y Agid; M Martinez; F Clerget-Darpoux
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

Review 3.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

4.  Effects of apolipoprotein E-epsilon4 and -epsilon2 in amnestic mild cognitive impairment and dementia in Shanghai: SCOBHI-P.

Authors:  Amy R Borenstein; James A Mortimer; Gerard D Schellenberg; Charles DeCarli; Cathleen Copenhaver; Douglas Galasko; David P Salmon; Ronald Petersen
Journal:  Am J Alzheimers Dis Other Demen       Date:  2010-02-08       Impact factor: 2.035

Review 5.  Use of genetic variation as biomarkers for Alzheimer's disease.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

6.  SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele.

Authors:  M Lehtovirta; H Soininen; M P Laakso; K Partanen; S Helisalmi; A Mannermaa; M Ryynänen; J Kuikka; P Hartikainen; P J Riekkinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

7.  Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism.

Authors:  M Lehtovirta; J Kuikka; S Helisalmi; P Hartikainen; A Mannermaa; M Ryynänen; H Soininen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

Review 8.  Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 9.  Endophenotypes in normal brain morphology and Alzheimer's disease: a review.

Authors:  C Reitz; R Mayeux
Journal:  Neuroscience       Date:  2009-04-09       Impact factor: 3.590

10.  APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.

Authors:  Sigrid B Sando; Stacey Melquist; Ashley Cannon; Michael L Hutton; Olav Sletvold; Ingvild Saltvedt; Linda R White; Stian Lydersen; Jan O Aasly
Journal:  BMC Neurol       Date:  2008-04-16       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.